Adjuvant platinum-based chemotherapy for early stage cervical cancer (Q24239896)

1

0 references

Paula Pohlmann

object named as

Paula R Pohlmann

5

0 references

Mary C Bozzetti

object named as

Mary C Bozzetti

4

0 references

author name string

Lídia RF Medeiros

2

0 references

Maria I Edelweiss

3

0 references

Airton T Stein

Cochrane Database of Systematic Reviews

6

0 references

publication date

8 July 2009

0 references

published in

0 references

cites work

Adjuvant simultaneous radiochemotherapy after operated uterine cervix carcinoma in high risk situation. Results of a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

Adjuvant therapy in cervical cancer patients with high risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

Review of survival analyses published in cancer journals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

Mitomycin C adjuvant chemotherapy after Wertheim's hysterectomy for stage IB cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Quality of life and the patient with cancer. Individual and policy implications

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Adjuvant chemotherapy and radiation in patients with poor prognostic stage Ib/IIa cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Adjuvant postoperative radiation: what size target?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Generalized Linear Models

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

An evaluation of chemotherapy in patients with cancer of the cervix and lymph node metastases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

The potential for adjuvant therapy in early-stage cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Early cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched-control study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Carcinoma of the cervix uteri.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

The role of radical surgery followed by adjuvant therapy for high-risk early-stage cervical carcinoma patients with pelvic lymph node metastasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Traditional management of invasive cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

New developments in the treatment of invasive cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Adjuvant therapy for high-risk, early stage cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Adjuvant therapy in gynecologic malignancies. Ovarian, cervical, and endometrial cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Long-term results of sequential postoperative treatment with vincristine, bleomycin, mitomycin c, cis-platin and radiotherapy after surgery for high-risk patients with cervical carcinoma stage IB-IIA

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Postoperative adjuvant therapy in early invasive cervical cancer patients with histopathologic high-risk factors.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Adjuvant chemotherapy of cervix carcinoma--results of a phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

[Adjuvant radio- and chemotherapy in cervix carcinoma]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

[Results of adjuvant chemotherapy of operated high risk cervix carcinoma]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Adjuvant cytotoxic chemotherapy following Wertheim radical hysterectomy for cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021

Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005342.PUB2

7 January 2021